Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Eckert, Franziska ^a   Alloussi, Saladin ^a   Paulsen, Frank ^a   Bamberg, Michael ^a   Zips, Daniel ^a   Spillner, Patrick ^a   Gani, Cihan ^a   Kramer, Ulrich ^a   Thorwarth, Daniela ^a   Schilling, David ^a   Müller, Arndt Christian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Dose escalation; Hydrogel spacer; Intensity modulated radiotherapy; Prostate cancer; Rectal toxicity

Indexed keywords

MACROGOL;

AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; EVALUATION; GASTROINTESTINAL TOXICITY; HUMAN; HYDROGEL; HYDROGEL SPACER; INJECTION; INTENSITY MODULATED RADIATION THERAPY; MALE; MEDICAL DEVICE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PROSPECTIVE STUDY; PROSTATE; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE ESCALATION; RECTUM; RECTUM TOXICITY; TREATMENT PLANNING;

ADENOCARCINOMA; AGED; DOSE FRACTIONATION; FEASIBILITY STUDIES; GERMANY; HUMANS; HYDROGEL; INJECTIONS; KALLIKREINS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872445391     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-27     Document Type: Article

References (30)

1. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009, 74(5):1405-1418. 10.1016/j.ijrobp.2008.10.091, 19616743.
2. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. German S3-Guideline 2011, Version 2.0 - 1. Aktualisierung 2011, 1-297. http://www.leitlinienprogramm-onkologie.de.
3. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, Van Der Kwast T, Wiegel T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011, 59(1):61-71. 10.1016/j.eururo.2010.10.039, 21056534.
4. Kuban D, Pollack A, Huang E, Levy L, Dong L, Starkschall G, Rosen I. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57(5):1260-1268. 10.1016/S0360-3016(03)00772-7, 14630260.
5. Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73(3):685-691. 10.1016/j.ijrobp.2008.04.063, 18718725.
6. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(4):1124-1129. 10.1016/j.ijrobp.2007.11.044, 18313526.
7. Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, Incrocci L, Lebesque JV. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72(4):980-988. 10.1016/j.ijrobp.2008.02.073, 18495377.
8. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8(6):475-487. 10.1016/S1470-2045(07)70143-2, 17482880.
9. Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys 2010, 77(3):773-783. 10.1016/j.ijrobp.2009.05.052, 2937212, 19836155.
10. Wilder RB, Barme GA, Gilbert RF, Holevas RE, Kobashi LI, Reed RR, Solomon RS, Walter NL, Chittenden L, Mesa AV, et al. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77(3):824-830. 10.1016/j.ijrobp.2009.05.069, 20510195.
11. Prada PJ, Gonzalez H, Menendez C, Llaneza A, Fernandez J, Santamarta E, Ricarte PP. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 2009, 8(2):210-217. 10.1016/j.brachy.2008.11.010, 19213607.
12. Noyes WR, Hosford CC, Schultz SE. Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys 2012, 82(5):1918-1922. 10.1016/j.ijrobp.2011.02.034, 21514738.
13. Ben-Yosef R, Paz A, Levy Y, Alani S, Muncher Y, Shohat S, Domb A, Corn B. A novel device for protecting rectum during prostate cancer irradiation: in vivo data on a large mammal model. J Urol 2009, 181(3):1401-1406. 10.1016/j.juro.2008.11.010, 19157458.
14. Pinkawa M, Corral NE, Caffaro M, Piroth MD, Holy R, Djukic V, Otto G, Schoth F, Eble MJ. Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol 2011, 100(3):436-441. 10.1016/j.radonc.2011.09.005, 21963289.
15. Susil RC, McNutt TR, DeWeese TL, Song D. Effects of prostate-rectum separation on rectal dose from external beam radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76(4):1251-1258. 10.1016/j.ijrobp.2009.07.1679, 3115781, 19939577.
16. Hatiboglu G, Pinkawa M, Vallee JP, Hadaschik B, Hohenfellner M. Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int 2012,
17. Wilder RB, Barme GA, Gilbert RF, Holevas RE, Kobashi LI, Reed RR, Solomon RS, Walter NL, Chittenden L, Mesa AV, et al. Cross-linked hyaluronan gel improves the quality of life of prostate cancer patients undergoing radiotherapy. Brachytherapy 2011, 10(1):44-50. 10.1016/j.brachy.2009.12.005, 20591748.
18. Baum C, Alber M, Birkner M, Nusslin F. Robust treatment planning for intensity modulated radiotherapy of prostate cancer based on coverage probabilities. Radiother Oncol 2006, 78(1):27-35. 10.1016/j.radonc.2005.09.005, 16216359.
19. Alber M. Normal tissue dose-effect models in biological dose optimisation. Z Med Phys 2008, 18(2):102-110.
20. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31(5):1341-1346. 10.1016/0360-3016(95)00060-C, 7713792.
21. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S123-129. 3319467, 20171506.
22. Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, Eble MJ. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 2011, 187(8):479-484. 10.1007/s00066-011-2249-z, 21789739.
23. Vordermark D, Guckenberger M, Baier K, Markert K. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity-modulated brachytherapy or EBRT for prostate cancer patients: in regard to Prada et al. (Int J Radiat Oncol Biol Phys 2007;69:95-102.). Int J Radiat Oncol Biol Phys 2008, 71(1):316-317.
24. Tucker SL, Thames HD, Michalski JM, Bosch WR, Mohan R, Winter K, Cox JD, Purdy JA, Dong L. Estimation of alpha/beta for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys 2011, 81(2):600-605. 10.1016/j.ijrobp.2010.11.080, 3163802, 21377288.
25. Budaus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, Wiegel T. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 2012, 61(1):112-127. 10.1016/j.eururo.2011.09.027, 22001105.
26. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006, 176(4 Pt 1):1415-1419.
27. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68(5):1424-1430. 10.1016/j.ijrobp.2007.01.067, 17544601.
28. Vora SA, Wong WW, Schild SE, Ezzell GA, Halyard MY. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68(4):1053-1058. 10.1016/j.ijrobp.2007.01.043, 17398023.
29. Lamb MN, Trabinino L, Hackford A. Patients' perspectives on fecal incontinence after brachytherapy for localized prostate cancer. Dis Colon Rectum 2011, 54(5):615-621. 10.1007/DCR.0b013e318207f85f, 21471764.
30. Fiorino C, Rancati T, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, et al. Late fecal incontinence after high-dose radiotherapy for prostate cancer: better prediction using longitudinal definitions. Int J Radiat Oncol Biol Phys 2012, 83(1):38-45. 10.1016/j.ijrobp.2011.06.1953, 21985939.